Ignite Creation Date:
2024-05-06 @ 8:51 AM
Last Modification Date:
2024-10-26 @ 12:05 PM
Study NCT ID:
NCT02831673
Status:
COMPLETED
Last Update Posted:
2023-08-24
First Post:
2016-07-08
Brief Title:
An Efficacy Safety and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus TenofovirEmtricitabine in Treatment naïve HIV Infected Subjects Gemini 1
Sponsor:
Organization:
ViiV Healthcare
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
719
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: